Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2012

View Archived Issues

Phase Ib/IIa study of ISIS-SMNRx commences

Biogen Idec and Sobi report topline results from phase III A-LONG trial

Preliminary results demonstrate good safety and efficacy for 3F8 + NK cells in neuroblastoma

Omeros begins enrollment in phase I trial evaluating OMS-824

Dynavax to begin phase I studies of TLR9 agonist for asthma

Portola, Bristol-Myers Squibb and Pfizer sign collaboration agreement

Navidea Biopharmaceuticals resubmits Lymphoseek NDA

Lilly Japan and Chugai to terminate Evista comarketing agreement in Japan

FDA approves Xarelto for use in three new indications

Addex reports topline data from second part of phase IIa ADX-71149 study

European authorities accept Ferring's MAA for MVDS in induction of labor

Biomedical Catalyst awards grants for development of healthcare technologies

PDA-001 induces clinical response in patients with Crohn's disease

Tesaro commences first clinical trial of its ALK inhibitor

[18F]-FE-PE2I investigated in healthy controls and patients with Parkinson's disease

Maresin 1 demonstrates analgesic activity

Vardenafil rescues CFTR function across rectal mucosa

New immunosuppressive compounds presented by Chinese researchers

Chinese group patents novel antipsychotic agents

Progress of EXC-001 triggers payment to Isis Pharmaceuticals

Bayer Schering Pharma synthesizes new protein kinase inhibitors

Siena Biotech presents new Wnt signaling inhibitors

Antitope to develop new biologic ANT-2034 for multiple sclerosis

Bioniche Life Sciences discontinues phase III Urocidin trial

Votubia obtains European approval for TSC-associated renal angiomyolipoma

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...